These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38315793)

  • 1. Trends in Anti-Vascular Endothelial Growth Factor Original Medicare Part B Claims in the United States, 2014-2019.
    Desai S; Sekimitsu S; Rossin EJ; Zebardast N
    Ophthalmic Epidemiol; 2024 Oct; 31(5):468-477. PubMed ID: 38315793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
    Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
    Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
    JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
    Glasser DB; Parikh R; Lum F; Williams GA
    Ophthalmology; 2020 Dec; 127(12):1688-1692. PubMed ID: 32544559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
    Han E; Baisiwala S; Jain A; Bundorf MK; Pershing S
    Am J Ophthalmol; 2017 Oct; 182():133-140. PubMed ID: 28784553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
    Zhang C; Friedman S; Mruthyunjaya P; Parikh R
    Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
    Baisiwala S; Bundorf MK; Pershing S
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
    Hollingworth W; Jones T; Reeves BC; Peto T
    BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of International Pricing Index Models on Anti-Vascular Endothelial Growth Factor (VEGF) Drug Costs in the United States.
    Choi S; Chen EM; Chen D; Sridhar J; Parikh R
    Semin Ophthalmol; 2022 Jan; 37(1):23-28. PubMed ID: 33822670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
    van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
    PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
    Singh N; Chang JS; Rachitskaya AV
    Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
    Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
    Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries.
    Thakore RV; Greenberg PB; Behrens JJ; French DD
    JAMA Ophthalmol; 2016 Sep; 134(9):1071-2. PubMed ID: 27366859
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of Anti-Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015.
    Berkowitz ST; Sternberg P; Feng X; Chen Q; Patel S
    JAMA Ophthalmol; 2019 Aug; 137(8):921-928. PubMed ID: 31219520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.